非小細胞肺がん（NSCLC）：2032年までの疫学予測

非小細胞肺がん（NSCLC）は肺がんの中で最も一般的なタイプで、肺がん全体の約85％を占めます。NSCLCは、肺の内壁を構成する健康な細胞が変化し、制御不能に増殖して腫瘍を形成することから始まります。NSCLCは肺のどこからでも始まり、非扁平上皮がんと扁平上皮がんという異なる組織学的サブタイプに分類することができます。NSCLCの正確な原因はわかっていませんが、肺がんの主要な危険因子は喫煙です。喫煙歴のない人や有害な化学物質への暴露歴のない人の多くも肺がんを発症する可能性があり、発病との遺伝的関連が示唆されています。

当レポートでは、主要8ヶ国市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本、カナダ）における非小細胞肺がん（NSCLC）の危険因子、併存疾患、世界および過去の疫学動向について概説し、クローン病の診断済み発症例と診断済み有病率に関する10年間の疫学予測などをまとめています。

目次

第1章 非小細胞肺がん：エグゼクティブサマリー

第2章 疫学

• 病気の背景
• リスク要因と合併症
• 世界と歴史の動向
• 主要8ヶ国予測調査手法
• 非小細胞肺がんの疫学的予測（2022年～2032年）
  • 診断済み非小細胞肺がんの診断例
  • 非小細胞肺がんの発症例、年齢別
  • 非小細胞肺がんの発症例、性別
  • 非小細胞肺がんの診断済み症例数、ステージ別
  • 非小細胞肺がんの診断済み症例数、組織学的タイプ別
  • 非小細胞肺がんの診断済み症例数、免疫療法バイオマーカー別
  • 非扁平上皮がんおよび扁平上皮がんの診断症例、ゲノムバイオマーカー別
  • 5年間の非小細胞肺がんの診断例
• 議論
  • 疫学的予測の洞察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

• Table 1: Summary of added and removed data types
• Table 2: Summary of updated data types
• Table 3: Risk factors and comorbidities for Lung Cancer
• Table 4: 8MM, diagnosed incident cases of NSCLC by stage, N, both sexes, ages >=18 years, 2022
• Table 5: 8MM, diagnosed incident cases of non-squamous and squamous NSCLC by immunotherapy biomarkers, N, both sexes, ages >=18 years, 2022
• Table 6: 8MM, diagnosed incident cases of non-squamous NSCLC by genomic biomarkers, N, both sexes, ages >=18 years, 2022
• Table 7: 8MM, diagnosed incident cases of squamous NSCLC by genomic biomarkers, N, both sexes, ages >=18 years, 2022

List of Figures

• Figure 1: 8MM, diagnosed incident cases of NSCLC, both sexes, N, ages >=18 years, 2022 and 2032
• Figure 2: 8MM, five-year diagnosed prevalent cases of NSCLC, both sexes, N, ages >=18 years, 2022 and 2032
• Figure 3: 8MM, diagnosed incidence of NSCLC, men, cases per 100,000 population, ages >=18 years, 2012-32
• Figure 4: 8MM, diagnosed incidence of NSCLC, women, cases per 100,000 population, ages >=18 years, 2012-32
• Figure 5: 8MM, sources used to forecast the diagnosed incident cases of NSCLC
• Figure 6: 8MM, sources used to forecast the diagnosed incident cases of NSCLC by stage at diagnosis
• Figure 7: 8MM, sources used to forecast the diagnosed incident cases of NSCLC by histological type
• Figure 8: 8MM, sources used to forecast the diagnosed incident cases of non-squamous cell carcinoma by PDL1, TMB, EGFR, and KRAS mutations
• Figure 9: 8MM, sources used to forecast the diagnosed incident cases of non-squamous cell carcinoma by ALK, ROS1, RET, and HER2 mutations.
• Figure 10: 8MM, sources used to forecast the diagnosed incident cases of non-squamous cell carcinoma by BRAF, BRAF V600E, NTRK1, and MET Exon 14 mutations.
• Figure 11: 8MM, sources used to forecast the diagnosed incident cases of squamous cell carcinomas by PDL1, TMB, EGFR, and KRAS mutations.
• Figure 12: 8MM, sources used to forecast the diagnosed incident cases of squamous cell carcinomas by ALK, ROS1, RET, and HER2 mutations.
• Figure 13: 8MM, sources used to forecast the five-year diagnosed prevalent cases of NSCLC in the 8MM.
• Figure 14: 8MM, diagnosed incident cases of NSCLC, N, both sexes, ages >=18 years, 2022
• Figure 15: 8MM, diagnosed incident cases of NSCLC by age, N, both sexes, 2022
• Figure 16: 8MM, diagnosed incident cases of NSCLC by sex, N, ages >=18 years, 2022
• Figure 17: 8MM, diagnosed incident cases of NSCLC by histological subtype, N, both sexes, ages >=18 years, 2022
• Figure 18: 8MM, five-year diagnosed prevalent cases of NSCLC, N, both sexes, >=18 years, 2022

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases (National Cancer Institute, 2020). NSCLC begins when healthy cells that make up the lining of the lungs change and grow out of control, forming a tumor. NSCLC can begin anywhere in the lungs and can be categorized into different histological subtypes: non-squamous cell carcinomas (which includes adenocarcinoma, large cell carcinoma, and other types such as undifferentiated or not otherwise specified carcinomas) and squamous cell carcinomas (Cleveland Clinic, 2022). The exact cause of NSCLC is not known, however, the leading risk factor for lung cancer is smoking. Many people with no smoking history or exposure to harmful chemicals can develop lung cancer too, suggesting a genetic link to disease development (Cancer.Net, 2022).

Scope

The Non-Small Cell Lung Cancer report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for NSCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of NSCLC. The diagnosed incident cases of NSCLC are segmented by age (starting at ages 18-29 years and then in 10-year age groups up to age 80 years and older), sex, stage at diagnosis (stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV), and histological subtypes: non-squamous cell carcinoma, which includes adenocarcinoma, large cell carcinoma, and others; and squamous cell carcinoma). The diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas are further segmented by genetic mutations. Additionally, this report includes a forecast for the five-year diagnosed prevalent cases of NSCLC. This epidemiology forecast for NSCLC is supported by data obtained from country-specific oncology registries, peer-reviewed articles, and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast for diagnosed incident cases of NSCLC across these markets.

Reasons to Buy

The Non-Small Cell Lung Cancer Epidemiology series will allow you to -

Develop business strategies by understanding the trends shaping and driving the global NSCLC markets.

Quantify patient populations in the global NSCLC markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NSCLC therapeutics in each of the markets covered.

Understand magnitude of the NSCLC population by age, sex, stage at diagnosis, histology, immunotherapy biomarkers and genetic mutations.

Table of Contents

Table of Contents

• About GlobalData

1 Non-Small Cell Lung Cancer: Executive Summary

• 1.1 Catalyst
• 1.2 Related Reports
• 1.3 Upcoming Reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 8MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumption and methods: diagnosed incident cases of NSCLC
  • 2.4.4 Forecast assumptions and methods: diagnosed incident cases of NSCLC by stage at diagnosis
  • 2.4.5 Forecast assumptions and methods: diagnosed incident cases of NSCLC by histological type
  • 2.4.6 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by immunotherapy biomarker
  • 2.4.7 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by genetic biomarkers
  • 2.4.8 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by genetic biomarker
  • 2.4.9 Forecast assumptions and methods: diagnosed incident cases of non-squamous cell carcinomas and squamous cell carcinomas by genetic biomarker
  • 2.4.10 Forecast assumptions and methods: five-year diagnosed prevalent cases of NSCLC
• 2.5 Epidemiological forecast for NSCLC (2022-32)
  • 2.5.1 Diagnosed incident cases of NSCLC
  • 2.5.2 Age-specific diagnosed incident cases of NSCLC
  • 2.5.3 Sex-specific diagnosed incident cases of NSCLC
  • 2.5.4 Diagnosed incident cases of NSCLC by stage
  • 2.5.5 Diagnosed incident cases of NSCLC by histological type
  • 2.5.6 Diagnosed incident cases of NSCLC by immunotherapy biomarker
  • 2.5.7 Diagnosed incident cases of non-squamous and squamous NSCLC by genomic biomarker
  • 2.5.8 Five-year diagnosed prevalent cases of NSCLC
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
• Contact Us